Skip to main content

Commercial feasibility of targeting the histone methyltransferase SETD8 in cancer: New chemical entities and biomarkers.

Project description

Clinical development of SETD8 inhibitors

Work in the ERC-funded project RSHEALTH has made significant progress in developing inhibitors of SETD8, a histone methyltransferase. Overexpressed in several cancers, it plays significant roles in DNA replication and repair. However, all available SETD8 inhibitors have low potency and poor pharmacological characteristics, and none have progressed to the clinic. At the same time, recent research identified SETD8 as a specific vulnerability in high-risk neuroblastoma and MYC-driven medulloblastomas. The EU-funded TARGETSET project will build on RSHEALTH results and the experience of transferring the inhibitors to the industry, facilitating the clinical development of SETD8 inhibitors. The project will improve inhibitors’ quality, valorise them in preclinical cancer models and develop companion biomarkers for patient stratification.

Host institution

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III
Net EU contribution
€ 150 000,00
Address
C Melchor Fernandez Almagro 3
28029 Madrid
Spain

See on map

Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Research Organisations
Other funding
No data

Beneficiaries (1)

FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III
Spain
Net EU contribution
€ 150 000,00
Address
C Melchor Fernandez Almagro 3
28029 Madrid

See on map

Region
Comunidad de Madrid Comunidad de Madrid Madrid
Activity type
Research Organisations
Other funding
No data